Abbott India Ltd. - Quarterly/Annual Result Disclosures and Notes dated 31 Mar 2021
Auditor and Management Disclosures and Notes for the annual results dated 31 Mar 2021
NOTES :
1. The above financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on May 18, 2021.
2. The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
3. The figures for the quarter ended March 31, 2021 and quarter ended March 31, 2020 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year which were only reviewed and not subjected to audit.
4. The Code on Social Security, 2020 (“the Code”) has been published in the Official Gazette in September 29, 2020. The final Rules and effective date are yet to be notified. The Company is assessing the impact of the Code and the rules thereunder and will give appropriate impact of the same in its financial statements, post notification of the same.
5. The Board of Directors of the Company have recommended a final dividend of Rs.120 per equity share of Rs.10 each and special dividend of Rs.155 per equity shares of Rs. 10 each for the year ended March 31, 2021 (March 31, 2020 : final dividend of Rs.107 and special dividend of Rs.143), subject to approval of the shareholders at the ensuing Annual General Meeting.
6. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
7. Figures for the previous periods have been regrouped/reclassified wherever considered necessary.